XML 54 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Acquisition of EGEN Assets (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2016
Jun. 20, 2014
Jun. 20, 2014
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Asset impairment charges, total           $ 2,400,000      
Business Combination, Consideration Transferred, Liabilities Incurred               $ 4,500,000 $ 2,500,000
Finite-lived intangible assets, net, ending balance           511,463 $ 738,779 568,292 795,608
Purchase Agreement [Member]                  
Finite-lived intangible assets, net, ending balance           511,463   568,292  
Finite-lived intangible assets, accumulated amortization           1,079,751   1,022,922  
IPR&D Drug Technology Platforms [Member]                  
Asset impairment charges, total     $ 1,400,000            
EGEN Inc [Member]                  
Potential future earn-out payments       $ 30,400,000 $ 30,400,000        
Payments to Acquire Businesses, Gross         $ 3,000,000        
Stock issued during period, shares, acquisitions         241,590        
Business Combination, Consideration Transferred, Liabilities Incurred       13,900,000     12,800,000 $ 8,900,000 $ 12,500,000
Goodwill, acquisition           2,000,000      
EGEN Inc [Member] | Purchase Agreement [Member]                  
Finite-lived intangible assets acquired           $ 1,600,000      
Finite-lived intangible asset, useful life           7 years      
Amortization expense           $ 56,829 $ 56,829    
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]                  
Asset impairment charges, total $ 9,400,000 $ 9,400,000              
EGEN Inc [Member] | Ovarian Cancer [Member]                  
Finite-lived intangible assets, net, ending balance           13,300,000      
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]                  
Indefinite lived intangible assets           $ 24,200,000      
EGEN Inc [Member] | Maximum [Member]                  
Total purchase price for the asset acquisition         $ 44,400,000        
Potential future earn-out payments       $ 30,400,000 $ 30,400,000